Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Youwei Bi

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid TumorsElizabeth S Duke, Diana Bradford, Michelle Marcovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerMichael J Fusco, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMichael I Barbato, Diana Bradford, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade GliomaSonia Singh, Diana Bradford, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2022
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsElizabeth S Duke, Liza Stapleford, Nicole Drezner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLCOladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or AlterationsLuckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid TumorsElizabeth S Duke, Diana Bradford, Michelle Marcovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerMichael J Fusco, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMichael I Barbato, Diana Bradford, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade GliomaSonia Singh, Diana Bradford, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2022
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsElizabeth S Duke, Liza Stapleford, Nicole Drezner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLCOladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or AlterationsLuckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Pageof 4